anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention relates to a dry powder pharmaceutical composition for pulmonary delivery for treating lymphangioleiomyomatosis in a human in need thereof. Composition contains micronised rapamycin, carrier particles, wherein carrier comprises a mixture of two different lactose carriers, and one or more optional excipients selected from a phospholipid and a metal salt of a fatty acid. Micronised rapamycin has mass median aerodynamic diameter (MMDA) from 1 to 5 microns. Rapamycin is the only therapeutic substance in the composition. Dry powder of rapamycin is delivered by inhaler. Also described is a method of treating lymphangioleiomyomatosis by inhalation of a dry powdered rapamycin composition.EFFECT: composition according to the invention provides high local concentration of rapamycin in lung tissue with an inhalation route.18 cl, 8 dwg, 9 tbl, 7 ex
Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
The object of the present invention is a method of manufacturing a floating tablet with extended interaction of therapeutic substances with stomach mucosa, comprising the steps of weighing therapeutic substances, sugar alcohols, acid polymers and anti-adhesion and lubricating substances, mixing them together, pouring into the tablet press hopper and pressing tablets having the diameter of 4 to 28 mm, using pressing force of 50 to 100,000, the therapeutic substance being preferably a compound selected from the group containing: pioglitazone hydrochloride, cephalexin, potassium losartan, captopril, diltiazem, chlorhexidine hydrochloride, and the acid polymer constitutes 0.5% - 94.9%wt. of the mixture, sugar alcohols constitute 5.0 - 99.4%wt. of the mixture, anti-adhesive and lubricating substances constitute 0.1% - 0.5%wt. of the mixture, The object of the present invention is also a pharmaceutic composition containing a therapeutic substance, sugar alcohols, acidic polymers of organic acids, and anti-adhesive and lubricating substances, the therapeutic substance being preferably a compound selected from the group containing: pioglitazone hydrochloride, cephalexin, potassium losartan, captopril, diltiazem, and the acid polymer constitutes 0.5% - 94.9%wt. of the composition, sugar alcohols constitute 5.0 - 99.4%wt. of the composition, anti-adhesive and lubricating substances constitute 0.1%-1.5%wt. of the composition,
Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
Predicting the course of kidney disease in individuals with both type 1 and type 2 diabetes mellitus (DM) is a significant clinical and policy challenge. In several regions, DM is now the leading cause of end-stage renal disease. The aim of this study to identify both modifiable and non-modifiable risk factors, along with clinical markers and coexisting conditions, that increase the likelihood of stage 3-5 chronic kidney disease (CKD) development in individuals with type 2 DM in the United Arab Emirates (UAE). This was a single-center retrospective cohort study based on data derived from electronic medical records of UAE patients with DM who were registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021. Type 2 DM patients aged ≥ 18 years who had serum HbA1c levels ≥ 6.5% were included in the study. Patients with type 1 DM, who had undergone permanent renal replacement therapy, who had under 1 year of follow-up, or who had missing or incomplete data were excluded from the study. Factors associated with diabetic patients developing stage 3-5 CKD were identified through Cox regression analysis and a fine and gray competing risk model to account for competing events that could potentially hinder the development of CKD. A total of 1003 patients were recruited for the study. The mean age of the study cohort at baseline was 70.6 ± 28.2 years. Several factors were found to increase the risk of developing stage 3-5 CKD: advancing age (HR 1.005, 95% CI 1.002-1.009, p = 0.026), a history of hypertension (HR 1.69, 95% CI 1.032-2.8, p = 0.037), a history of heart disease (HR 1.49, 95% CI 1.16-1.92, p = 0.002), elevated levels of serum creatinine (HR 1.006, 95% CI 1.002-1.010, p = 0.003), decreased levels of estimated glomerular filtration rate (eGFR) (HR 0.943, 95% CI, 0.938-0.947; p < 0.001), and the use of beta-blockers (HR 139, 95% CI 112-173, p = 0.003). Implementing preventative measures, initiating early interventions, and developing personalized care plans tailored to address specific risk factors are imperative for reducing the impact of CKD. Additionally, the unforeseen findings related to eGFR highlight the ongoing need for research to deepen our understanding of the complexities of kidney disease.
FIELD: food industry. ^ SUBSTANCE: invention is related to phytotherapy. The biologically active supplement possessing antidepressant effect contains L-tryptophan, linseed-oil and vegetal components. The vegetal components are represented by oil extract of mother-of-thyme herb, common origanum herb, St.-John's wort herb, sandy everlasting blossom, common valerian root with rhizomes and elecampane root with rhizomes taken in a ratio of 0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2 accordingly and a dried water extract produced by way of expression of the same components after oil extraction. The biologically active supplement production method envisages mixture of the above components. The oil extract is produced by extracting the vegetal raw material with vegetable oil at a temperature of 50-70C during 5-10 h with subsequent separation of the raw material. The water extract is produced by extracting the raw material, expressed after oil extraction, with water at a temperature of 50-70C during 5-10 h with subsequent filtrate filtering and drying to produce the dry solid. ^ EFFECT: invention enables production of a supplement that is efficient in therapy of different forms of stress including sleep disturbance with patients of different age groups, aggressiveness, instability of temper, state of anxiety, has a positive effect on normalisation of the brain electrical activity indices and basic brain blood circulation indices and possessing antioxidant action. ^ 9 cl, 4 tbl, 1 ex
BACKGROUND Pyoderma gangrenosum (PG) is a neutrophilic inflammatory disease associated with inflammatory and autoimmune conditions and malignancies. Previously identified links between PG and cancer have included hematological malignancies, solid-organ tumors such as gastric adenocarcinoma, and breast cancer. While specific histologic subtypes of breast cancer such as ductal carcinoma have been associated with PG of the extremities, the literature is limited on the association between PG and cutaneous metastatic lobular carcinoma. CASE REPORT We describe the case of an 84-year-old woman with recurrent cutaneous metastatic lobular carcinoma of the left anterior chest with concurrent pyoderma gangrenosum on her bilateral lower extremities. The patient was initially diagnosed with lobular carcinoma of the breast and underwent a left breast mastectomy and was in remission. One year later, she developed 2 lower-extremity ulcerations, which at the time were attributed to an injury and underlying venous stasis. She was referred to a wound care clinic, where the lesions worsened with surgical debridement. Six years later, she presented to the dermatology clinic with a rash on her chest wall and worsening of the ulcerations on her ankles bilaterally. Biopsies revealed lobular carcinoma metastatic to the skin of her anterior chest wall and histopathology consistent with pyoderma gangrenosum on her ankles. CONCLUSIONS This case demonstrates a unique presentation of worsening pyoderma gangrenosum due to metastatic malignancy in conjunction with a cutaneous manifestation of lobular carcinoma.
The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
Brachytherapy is a type of radiotherapy used in cancer treatment. In this method, the radiation source is placed directly on the tumor or the area to be treated. In this way, high doses of radiation are applied only to the target area, while surrounding healthy tissues are less damaged. Brachytherapy is usually used in the treatment of certain types of cancer, such as prostate, cervix, breast, and skin cancer. Gynecological brachytherapy is the application of brachytherapy in the treatment of gynecological cancers. It can be used especially in cancers of the uterus, cervix, vagina, and vulva. This treatment method is performed by placing the radiation source in the area where the tumor is located. Brachytherapy can be used in combination with surgery, chemotherapy, or other types of radiotherapy in the treatment of these types of cancers. Factors such as cancer burden, the problem of achieving remission, and the need for patients to remain immobile during the procedure, which is performed in a room that needs to be isolated due to radiation, contribute to symptoms such as pain and anxiety before and during treatment. These symptoms can sometimes affect vital signs. The need for patients to remain immobile during brachytherapy, the need to be isolated in a room due to radiation, and the discomfort caused by the applicators also increase anxiety in women. Patients often experience fear and anxiety because there is insufficient information about brachytherapy that could help relieve their pain and anxiety. Despite the complexity of such a procedure and the significant patient population, there are few studies on women's experiences with brachytherapy.
The present invention relates to a forest frog's oviduct product and a processing method thereof, particularly to an instant full-content emulsive forest frog's oviduct product and a manufacturing method thereof. After the forest frog's oviduct and the water are made uniform, cells in whole-quality substances are completely broken by the technology of ultrasonic waves to release all contents and obtain the instant full-content emulsive forest frog's oviduct product. The finished product is obtained by the steps of sterilizing, filling, sealing and packing. The technology has the advantages that cells of forest frog's oviduct can be fully broken, biomacromolecules can be transformed into small molecules, and the forest frog's oviduct product can be instantly dissolved in water without obvious fishy smell. Therefore, the product can be directly added with water or with other drinks. In addition, instant full-content forest frog's oviduct emulsion can be combined with all nutrient substances with water solubility to produce an agent type instant composite forest frog's oviduct solid product.
Vildagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) and inhibits glucagon secretion and stimulates insulin secretion. This improves glycemia in subjects with type 2 diabetes with a very low risk for hypoglycemia. If hypoglycemia nevertheless develops, it is important that vildagliptin under such conditions does not inhibit glucagon secretion, since that would aggravate the hypoglycemia. It was indeed previously demonstrated in type 2 diabetes that vildagliptin dos not inhibit glucagon secretion during hypoglycemia. This study explores whether vildagliptin affects glucagon counterregulation during hypoglycemia in insulin-treated patients of type 2 diabetes. Vildagliptin is given, together with the on-going insulin therapy, for one month, whereafter hypoglycemia is induced under standardized conditions, and the glucagon response is determined, and compared to that after a month of placebo treatment. The hypoglycemia is induced bvy a standardized clamp procedure.
Patients with resectable pancreatic cancer will receive preoperative SBRT 2 to 4 weeks before surgery. And 4 weeks after surgery, adjuvant CTx will be administered for 6 months.
This invention provides for an isolated nucleic acid which encodes a wildtype human Beclin and a mutant human Beclin. This invention also provides a vector containing the isolated nucleic acid which encodes a wildtype human Beclin. This invention also provides for a method of producing a wildtype human Beclin. This invention also provides for a purified, wildtype human Beclin. This invention also provides for a method for determining whether a subject has a predisposition for cancer. This invention also provides a method for determining whether a subject has cancer. This invention also provides for a method for inhibiting cell proliferation in cells unable to regulate themselves. This invention also provides for a method for treating a subject who has cancer. This invention also provides for a pharmaceutical composition composed of the and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition composed of the wildtype human Beclin. This invention also provides a method for detecting a mutant human Beclin in a subject. This invention also provides a method for treating a subject unable to control apoptosis in the cells of the subject.
Group 4: These patients will be screened negative for the ACOG screening test and positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
The ancillary study will use mixed-methods combining quantitative and qualitative inquiry (interview/focus group and field notes) with administrative and health record data with some analyses including data collected from the parent CTN-0079 (NCT03544112) study. Further, qualitative data will be analyzed in the context of themes derived from CTN-0069 (NCT03023930) and CTN-0079. CTN-0079-A1 is planned to be conducted at two of the three sites of the parent study: (1) Catholic Medical Center, Manchester, New Hampshire; (2) Bellevue/NYU Health and Hospitals, New York, NY. Many of the methods, operating procedures, measures and forms will be retained or adapted from the parent study. However, CTN-0079-A1 is a new study in which lessons learned through the parent study have informed important design modifications necessary to improve study rigor and utility.

As in the parent study, CTN-0079, all clinical care (BUP and referral) will be delivered as part of each facility's clinical protocol, rather than as a research procedure. Implementation Facilitation (IF) activities will continue during ancillary trial preparation with a more intensive booster of IF activities occurring in the last month prior to trial commencement. Thereafter, all study IF support will cease and ancillary study data collection will begin. Data collection will occur over a course of approximately 12 months, divided into two 6-month study periods - the Post-IF and Maintenance Periods. A period of at least 6 months should separate the beginning of the Maintenance Period from the time of last study intervention.
Therapeutically active cpds. consisting of a chemical condensation product of a first antimalarially active cpd. with a second antimalarially active cpd. Preferred cpds. are those of formula (I): (I) A - N = N - B where A is the residue of a sulphonamide or sulphone (e.g. a residue of the formula: where M is H or a substd. homocyclic or heterocyclic aromatic residue); and B is the residue of a quinoline (e.g. a residue of the formula: where R1 is OH or alkoxy, R2 is a divalent straight or branched aliphatic residue and R3 and R4 are H or lower alkyl); cpds. where B is a naphthoquinone residue are also mentioned.
Arm A will include microsatellite-stable metastatic colorectal cancer patients who have no active liver metastasis. Patients are required to have received prior 5-Fu， oxaliplatin, and irinotecan treatment before enrollment.
<P>PROBLEM TO BE SOLVED: To provide a gel pack material having moderate adhesiveness to skin and good handleability and sustaining good moisture retaining effects on the skin even when used over a long period of time and to provide a method for producing the gel pack material.  <P>SOLUTION: The gel pack material is obtained by laminating a hydrous gel layer onto the surface of a supporting substrate. The method for producing the gel pack material is provided. The hydrous gel layer is composed of a gel-like composition composed of at least water, a polyacrylic acid compound, a polyhydric alcohol, an oil-based ingredient and a dispersion aid. The content of the oil-based ingredient is a value within the range of 5-20 mass% when the total mass of the gel-like composition is 100 mass%.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The control group will be guided to use the same website although they will only have access to a restricted version of it, with the dietary recall feature plus general information about the Mediterranean diet. They will not receive specific recommendations to reduce red and processed meat or any other support or advice. Participants will be instructed to fill in as many 24h dietary recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. The rest of the clinical care will be as usual.
To evaluate the spatiotemporal trends and drivers of PM2.5-related health effects in Gansu Province since the implementation of the Air Pollution Prevention and Control Action Plan, the latest global exposure mortality model (GEMM) was adopted to estimate the health burden attributable to PM2.5 in Gansu Province from 2013 to 2020. The factor decomposition method was used to further quantify the main causes of the long-term changes in deaths attributable to PM2.5 pollution. The results showed that from 2013 to 2020, the population-weighted PM2.5 concentration in Gansu Province decreased by 34.57%, and the proportion of people exposed to areas with an annual average PM2.5 concentration exceeding 35 μg·m-3 decreased significantly from 72.89% to 11.61%. Moreover, the number of attributable deaths in Gansu Province declined from 12 826 (95%CI: 7 840-17 408) in 2 013 to 9 814 (95%CI: 6 407-13 036) in 2020, indicating a decrease of 23.48%. Attributable deaths from stroke, chronic obstructive pulmonary disease, lung cancer, and lower respiratory infection declined, whereas deaths from ischemic heart disease increased by 12.11%. Notably, individuals aged 60 years and older accounted for more than 80% of all age-related deaths. The number of deaths attributable to PM2.5 in central and eastern Gansu Province was significantly higher than that in the Hexi region, and most regions showed a downward trend. The contribution of the total population, age structure, baseline mortality rate, and PM2.5 concentration to the change in PM2.5-related deaths was -1.26%, 16.16%, -9.84%, and -28.55%, respectively. Overall, population aging and a decrease in PM2.5 concentration were the main factors contributing to the increase and decrease in PM2.5-related deaths, respectively. The active clean air policies in Gansu Province have reduced the health burden caused by PM2.5 pollution, but with the trend of population aging, a significant reduction in PM2.5 concentration will be needed in the future to avoid more attributable deaths.
A biologically active composition made up of core particles or surfaces which are coated with a layer which is designed to allow attachment of biochemically reactive pairs (BRP's) without denaturing the BRP. BRPs which may be attached include ligand-receptor pairs, enzyme-substrate pairs, drug-receptor pairs, catalyst-reactant pairs, toxin-ligand pairs, absorbant-absorbate pairs and adsorbant-adsorbate pairs. Also disclosed are biologically active compositions made up of biodegradable core particles which are coated with a layer that is designed to allow attachment of biologically active agents without denaturing them. The compositions may further include an exterior targeting membrane which provides selective targeting to specific receptors. In addition, biologically active compositions for use in gene therapy and other transfection procedures are disclosed. The compositions are composed of nanocrystalline core particles which are coated with a layer that is designed to allow attachment of transfection agents (DNA/RNA segments or antisense fragments) without denaturing them. The composition may further include an exterior targeting membrane which provides selective targeting of the transfection agents to specific cell receptors.
Doxorubicin (DOX) is the most commonly used anthracycline anticancer agent, while its clinical utility is limited by harmful side effects like cardiotoxicity. Numerous studies have elucidated that programmed cell death plays a significant role in DOX-induced cardiotoxicity (DIC). This review summarizes several kinds of programmed cell death, including apoptosis, pyroptosis, necroptosis, autophagy, and ferroptosis. Furthermore, oxidative stress, inflammation, and mitochondrial dysfunction are also important factors in the molecular mechanisms of DIC. Besides, a comprehensive understanding of specific signal pathways of DIC can be helpful to its treatment. Therefore, the related signal pathways are elucidated in this review, including sirtuin deacetylase (silent information regulator 2 [Sir2]) 1 (SIRT1)/nuclear factor erythroid 2-related factor 2, SIRT1/Klotho, SIRT1/Recombinant Sestrin 2, adenosine monophosphate-activated protein kinase, AKT, and peroxisome proliferator-activated receptor. Heat shock proteins function as chaperones, which play an important role in various stressful situations, especially in the heart. Thus, some of heat shock proteins involved in DIC are also included. Hence, the last part of this review focuses on the therapeutic research based on the mechanisms above.
<P>PROBLEM TO BE SOLVED: To provide a method of supplying cosmetics, sanitary drug product and the other medicine to an applied object such as the skin and applying the same, adding a further function to the cosmetics and medicine.  <P>SOLUTION: The cosmetics and medicine are electrolyzed and supplied to the applied object. The electrolysis is preferably performed by switching the polarity of power applied to an electrode at predetermined time intervals. As the supply method, preferably the electrolyzed cosmetics or medicine is supplied to the applied object by atomization. As an atomizing means, preferably a piezo oscillator provided with a porous plate is used.  <P>COPYRIGHT: (C)2006,JPO&NCIPI